{
  "_metadata": {
    "version": "2.2",
    "ticker": "EWTX",
    "asset_name": "edg7500",
    "last_updated": "2026-02-09",
    "sources": [
      {
        "id": "ewtx_extraction_20260209",
        "type": "ai_extraction",
        "title": "AI extraction from Edgewise EDG-7500 poster.pdf",
        "date": "2026-02-09",
        "model": "claude-sonnet-4-5-20250929"
      }
    ]
  },
  "asset": {
    "name": "EDG-7500",
    "company": "Edgewise Therapeutics",
    "ticker": "EWTX",
    "stage": "Phase 2",
    "modality": "",
    "one_liner": "EDG-7500 demonstrated robust efficacy across both obstructive and nonobstructive HCM with 89% (100mg dose) achieving complete LVOT-G response in oHCM and significant improvements in NT-proBNP, diastol"
  },
  "target": {
    "name": "Cardiac sarcomere",
    "biology": {
      "simple_explanation": "Novel cardiac sarcomere modulator designed to slow the rate of acto-myosin engagement and speed disengagement without inactivating the myosin motor head. Unlike cardiac myosin inhibitors, EDG-7500 does not inactivate the myosin motor and has not shown meaningful reductions in LVEF in preclinical or clinical studies to date."
    }
  },
  "mechanism": {
    "type": "Novel cardiac sarcomere modulator designed to slow the rate of acto-myosin engagement and speed disengagement without inactivating the myosin motor head. Unlike cardiac myosin inhibitors, EDG-7500 does not inactivate the myosin motor and has not shown meaningful reductions in LVEF in preclinical or clinical studies to date.",
    "how_it_works": "Novel cardiac sarcomere modulator designed to slow the rate of acto-myosin engagement and speed disengagement without inactivating the myosin motor head. Unlike cardiac myosin inhibitors, EDG-7500 does not inactivate the myosin motor and has not shown meaningful reductions in LVEF in preclinical or clinical studies to date."
  },
  "indications": {
    "lead": {
      "name": "Hypertrophic Cardiomyopathy (HCM) - both obstructive (oHCM) and nonobstructive (nHCM)",
      "patient_population": "29",
      "rationale": ""
    }
  },
  "clinical_data": {
    "extracted_edg7500": {
      "trial_name": [
        "CIRRUS-HCM: Multiple-dose, open-label Phase 2 study evaluating safety, tolerability, and effects on hemodynamics and functional capacity"
      ],
      "design": {
        "type": "CIRRUS-HCM: Multiple-dose, open-label Phase 2 study evaluating safety, tolerability, and effects on hemodynamics and functional capacity. Two cohorts: obstructive HCM (oHCM, N=17) and nonobstructive HCM (nHCM, N=12). Dose levels: 50 mg and 100 mg. Duration: at least 4 weeks with measurements at baseline, week 1, week 2, and week 4. Longer-term cohort exploring intra-patient dose optimization. No placebo control.",
        "population": "Hypertrophic cardiomyopathy patients with symptomatic disease (NYHA Class II-III). oHCM cohort had baseline resting LVOT-G \u226530 mmHg or Valsalva LVOT-G \u226550 mmHg (though 5 participants had gradients below these thresholds on Day 1). nHCM cohort had minimal/no obstruction.",
        "n": 29
      },
      "baseline_characteristics": {
        "age_yrs_mean_sd": [
          "61 (13)",
          "54 (19)"
        ],
        "female_n_%": [
          "12 (71%)",
          "7 (58%)"
        ],
        "bmi_kg_m\u00b2_mean_sd": [
          "28 (4)",
          "27 (4)"
        ],
        "pathogenic_sarcomere_variant_n_%": [
          "4 (24%)",
          "4 (33%)"
        ],
        "history_of_paroxysmal_af_flutter_n_%": [
          "1 (6%)",
          "2 (17%)"
        ],
        "icd_n_%": [
          "2 (12%)",
          "6 (50%)"
        ],
        "prior_srt_n_%": [
          "1 (6%)",
          "0%"
        ],
        "hypertension_n_%": [
          "11 (65%)",
          "2 (17%)"
        ],
        "diabetes_n_%": [
          "1 (6%)",
          "2 (17%)"
        ],
        "nyha_class_i_n_%": [
          "1 (6%)",
          "0%"
        ],
        "nyha_class_ii_n_%": [
          "10 (59%)",
          "6 (50%)"
        ],
        "nyha_class_iii_n_%": [
          "6 (35%)",
          "6 (50%)"
        ],
        "lvef_%_mean_sd": [
          "65 (4)",
          "61 (6)"
        ],
        "lvot-g_resting;_mmhg_mean_sd": [
          "59 (30)",
          "9 (6)"
        ],
        "lvot-g_valsalva;_mmhg_mean_sd": [
          "93 (32)",
          "14 (10)"
        ],
        "e'_mean_cm_s_mean_sd": [
          "6 (2)",
          "7 (2)"
        ],
        "maximal_lv_wall_thickness_mm_mean_sd": [
          "18 (2)",
          "18 (3)"
        ],
        "lavi_ml_m\u00b2_mean_sd": [
          "37 (13)",
          "31 (12)"
        ],
        "kccq-oss_mean_sd": [
          "63 (16)",
          "57 (22)"
        ],
        "kccq-css_mean_sd": [
          "69 (15)",
          "63 (23)"
        ],
        "nt-probnp_geometric_mean_median_iqr;_pg_": [
          "724 / 710 (381, 1074)",
          "782 / 715 (546, 1231)"
        ]
      },
      "efficacy_endpoints": {
        "resting_lvot_g_<30_mmhg": {
          "name": "Resting LVOT-G <30 mmHg",
          "population": "oHCM",
          "dose": "100 mg",
          "baseline": "59 (30) mmHg mean (SD)",
          "result": "89% responders",
          "change": null,
          "timepoint": "Week 4",
          "p_value": null,
          "n": 9,
          "confidence": "high"
        },
        "valsalva_lvot_g_<50_mmhg": {
          "name": "Valsalva LVOT-G <50 mmHg",
          "population": "oHCM",
          "dose": "100 mg",
          "baseline": "93 (32) mmHg mean (SD)",
          "result": "89% responders",
          "change": null,
          "timepoint": "Week 4",
          "p_value": null,
          "n": 9,
          "confidence": "high"
        },
        "nt_probnp_<150_pg/ml": {
          "name": "NT-proBNP <150 pg/mL",
          "population": "oHCM",
          "dose": "100 mg",
          "baseline": "724 pg/mL geometric mean",
          "result": "56% responders (5/9)",
          "change": null,
          "timepoint": "Week 4",
          "p_value": null,
          "n": 9,
          "confidence": "high"
        },
        "nyha_class_improvement_\u22651_class": {
          "name": "NYHA Class improvement \u22651 class",
          "population": "oHCM",
          "dose": "100 mg",
          "baseline": "NYHA II/III distribution",
          "result": "78% responders",
          "change": null,
          "timepoint": "Week 4",
          "p_value": null,
          "n": 9,
          "confidence": "high"
        },
        "kccq_oss_change": {
          "name": "KCCQ-OSS change",
          "population": "oHCM",
          "dose": "100 mg",
          "baseline": "63 (16) mean (SD)",
          "result": "Absolute change approximately +12 points",
          "change": "+12 points",
          "timepoint": "Week 4",
          "p_value": "NS",
          "n": 9,
          "confidence": "medium"
        },
        "kccq_css_clinical_improvement_distributi": {
          "name": "KCCQ-CSS clinical improvement distribution",
          "population": "nHCM",
          "dose": "50 mg and 100 mg combined",
          "baseline": "63 (23) mean (SD)",
          "result": "88% with clinical improvements: 25% very large (>20pt), 38% large (10-20pt), 25% moderate (5-10pt)",
          "change": null,
          "timepoint": "Week 4",
          "p_value": "NS at both doses",
          "n": 7,
          "confidence": "medium"
        },
        "nt_probnp_change": {
          "name": "NT-proBNP change",
          "population": "nHCM",
          "dose": "50 mg and 100 mg combined",
          "baseline": "782 pg/mL geometric mean",
          "result": "Rapid and robust reductions observed",
          "change": null,
          "timepoint": "Week 1-4",
          "p_value": null,
          "n": 12,
          "confidence": "high"
        },
        "early_diastolic_mitral_annular_velocity_": {
          "name": "Early diastolic mitral annular velocity (e') change",
          "population": "nHCM",
          "dose": "100 mg",
          "baseline": "7 (2) cm/s mean (SD)",
          "result": "Improvements observed",
          "change": null,
          "timepoint": "Week 1 onwards",
          "p_value": "Week 2: \u22640.05; Week 4: NS",
          "n": 12,
          "confidence": "high"
        },
        "lvef_change_from_baseline": {
          "name": "LVEF change from baseline",
          "population": "oHCM + nHCM combined",
          "dose": "All doses",
          "baseline": "65 (4)% oHCM, 61 (6)% nHCM",
          "result": "No meaningful reductions; no LVEF <50%",
          "change": "+2.5% for 4 nHCM participants with baseline LVEF <60%",
          "timepoint": "Throughout treatment period",
          "p_value": null,
          "n": 29,
          "confidence": "high"
        }
      },
      "time_course_data": [
        {
          "endpoint": "Resting LVOT-G",
          "unit": "mmHg",
          "data": [
            {
              "timepoint": "Baseline",
              "dose": "50 mg",
              "value": "approximately 60"
            },
            {
              "timepoint": "Week 1",
              "dose": "50 mg",
              "value": "approximately 40"
            },
            {
              "timepoint": "Week 2",
              "dose": "50 mg",
              "value": "approximately 30"
            },
            {
              "timepoint": "Week 4",
              "dose": "50 mg",
              "value": "approximately 35"
            },
            {
              "timepoint": "Baseline",
              "dose": "100 mg",
              "value": "approximately 60"
            },
            {
              "timepoint": "Week 1",
              "dose": "100 mg",
              "value": "approximately 25"
            },
            {
              "timepoint": "Week 2",
              "dose": "100 mg",
              "value": "approximately 20"
            },
            {
              "timepoint": "Week 4",
              "dose": "100 mg",
              "value": "approximately 18"
            }
          ]
        },
        {
          "endpoint": "Valsalva LVOT-G",
          "unit": "mmHg",
          "data": [
            {
              "timepoint": "Baseline",
              "dose": "50 mg",
              "value": "approximately 90"
            },
            {
              "timepoint": "Week 1",
              "dose": "50 mg",
              "value": "approximately 55"
            },
            {
              "timepoint": "Week 2",
              "dose": "50 mg",
              "value": "approximately 45"
            },
            {
              "timepoint": "Week 4",
              "dose": "50 mg",
              "value": "approximately 50"
            },
            {
              "timepoint": "Baseline",
              "dose": "100 mg",
              "value": "approximately 95"
            },
            {
              "timepoint": "Week 1",
              "dose": "100 mg",
              "value": "approximately 45"
            },
            {
              "timepoint": "Week 2",
              "dose": "100 mg",
              "value": "approximately 35"
            },
            {
              "timepoint": "Week 4",
              "dose": "100 mg",
              "value": "approximately 30"
            }
          ]
        },
        {
          "endpoint": "NT-proBNP",
          "unit": "% change from baseline",
          "data": [
            {
              "timepoint": "Baseline",
              "dose": "oHCM",
              "value": "0"
            },
            {
              "timepoint": "Week 1",
              "dose": "oHCM",
              "value": "approximately -40%"
            },
            {
              "timepoint": "Week 2",
              "dose": "oHCM",
              "value": "approximately -50%"
            },
            {
              "timepoint": "Week 4",
              "dose": "oHCM",
              "value": "approximately -30%"
            },
            {
              "timepoint": "End of Study",
              "dose": "oHCM",
              "value": "approximately -40%"
            },
            {
              "timepoint": "Baseline",
              "dose": "nHCM 50mg",
              "value": "0"
            },
            {
              "timepoint": "Week 1",
              "dose": "nHCM 50mg",
              "value": "approximately -50%"
            },
            {
              "timepoint": "Week 2",
              "dose": "nHCM 50mg",
              "value": "approximately -60%"
            },
            {
              "timepoint": "Week 4",
              "dose": "nHCM 50mg",
              "value": "approximately -55%"
            },
            {
              "timepoint": "Baseline",
              "dose": "nHCM 100mg",
              "value": "0"
            },
            {
              "timepoint": "Week 1",
              "dose": "nHCM 100mg",
              "value": "approximately -50%"
            },
            {
              "timepoint": "Week 2",
              "dose": "nHCM 100mg",
              "value": "approximately -55%"
            },
            {
              "timepoint": "Week 4",
              "dose": "nHCM 100mg",
              "value": "approximately -45%"
            }
          ]
        },
        {
          "endpoint": "Early diastolic mitral annular velocity (e')",
          "unit": "% change from baseline",
          "data": [
            {
              "timepoint": "Baseline (nHCM combined)",
              "dose": "all",
              "value": "0"
            },
            {
              "timepoint": "Week 1",
              "dose": "nHCM 50mg",
              "value": "approximately +10%"
            },
            {
              "timepoint": "Week 2",
              "dose": "nHCM 50mg",
              "value": "approximately +20%"
            },
            {
              "timepoint": "Week 4",
              "dose": "nHCM 50mg",
              "value": "approximately +25%"
            },
            {
              "timepoint": "Week 1",
              "dose": "nHCM 100mg",
              "value": "approximately +15%"
            },
            {
              "timepoint": "Week 2",
              "dose": "nHCM 100mg",
              "value": "approximately +25%"
            },
            {
              "timepoint": "Week 4",
              "dose": "nHCM 100mg",
              "value": "approximately +20%"
            },
            {
              "timepoint": "Baseline (oHCM)",
              "dose": "all",
              "value": "0"
            },
            {
              "timepoint": "Week 1",
              "dose": "oHCM",
              "value": "approximately +8%"
            }
          ]
        },
        {
          "endpoint": "KCCQ-OSS",
          "unit": "absolute change from baseline (points)",
          "data": [
            {
              "timepoint": "Baseline",
              "dose": "50 mg",
              "value": "0"
            },
            {
              "timepoint": "2 weeks",
              "dose": "50 mg",
              "value": "approximately +8"
            },
            {
              "timepoint": "4 weeks",
              "dose": "50 mg",
              "value": "approximately +10"
            },
            {
              "timepoint": "Baseline",
              "dose": "100 mg",
              "value": "0"
            },
            {
              "timepoint": "2 weeks",
              "dose": "100 mg",
              "value": "approximately +12"
            },
            {
              "timepoint": "4 weeks",
              "dose": "100 mg",
              "value": "approximately +12"
            }
          ]
        },
        {
          "endpoint": "KCCQ-CSS",
          "unit": "absolute change from baseline (points)",
          "data": [
            {
              "timepoint": "Baseline",
              "dose": "50 mg",
              "value": "0"
            },
            {
              "timepoint": "2 weeks",
              "dose": "50 mg",
              "value": "approximately +10"
            },
            {
              "timepoint": "4 weeks",
              "dose": "50 mg",
              "value": "approximately +12"
            },
            {
              "timepoint": "Baseline",
              "dose": "100 mg",
              "value": "0"
            },
            {
              "timepoint": "2 weeks",
              "dose": "100 mg",
              "value": "approximately +14"
            },
            {
              "timepoint": "4 weeks",
              "dose": "100 mg",
              "value": "approximately +15"
            }
          ]
        },
        {
          "endpoint": "NYHA Class Distribution",
          "unit": "percentage of patients",
          "data": [
            {
              "timepoint": "Baseline (50mg)",
              "dose": "Class I",
              "value": "14%"
            },
            {
              "timepoint": "Baseline (50mg)",
              "dose": "Class II",
              "value": "57%"
            },
            {
              "timepoint": "Baseline (50mg)",
              "dose": "Class III",
              "value": "29%"
            },
            {
              "timepoint": "Week 4 (50mg)",
              "dose": "Class I",
              "value": "29%"
            },
            {
              "timepoint": "Week 4 (50mg)",
              "dose": "Class II",
              "value": "57%"
            },
            {
              "timepoint": "Week 4 (50mg)",
              "dose": "Class III",
              "value": "14%"
            },
            {
              "timepoint": "Baseline (100mg)",
              "dose": "Class I",
              "value": "0%"
            },
            {
              "timepoint": "Baseline (100mg)",
              "dose": "Class II",
              "value": "56%"
            },
            {
              "timepoint": "Baseline (100mg)",
              "dose": "Class III",
              "value": "44%"
            },
            {
              "timepoint": "Week 4 (100mg)",
              "dose": "Class I",
              "value": "44%"
            },
            {
              "timepoint": "Week 4 (100mg)",
              "dose": "Class II",
              "value": "44%"
            },
            {
              "timepoint": "Week 4 (100mg)",
              "dose": "Class III",
              "value": "11%"
            }
          ]
        }
      ],
      "safety": {
        "summary": "",
        "teae_table": {
          "columns": [
            "Treatment-Emergent Adverse Events (TEAE)",
            "N=29 n (%)"
          ],
          "rows": [
            {
              "event": "Dizziness (mostly mild and transient in duration)",
              "values": [
                "8 (27.6%)"
              ]
            },
            {
              "event": "Upper respiratory tract infection",
              "values": [
                "5 (17.2%)"
              ]
            },
            {
              "event": "Atrial fibrillation",
              "values": [
                "4 (13.8%)"
              ]
            },
            {
              "event": "Influenza like illness",
              "values": [
                "3 (10.3%)"
              ]
            },
            {
              "event": "Palpitations",
              "values": [
                "3 (10.3%)"
              ]
            },
            {
              "event": "Constipation",
              "values": [
                "2 (6.9%)"
              ]
            },
            {
              "event": "Diarrhea",
              "values": [
                "2 (6.9%)"
              ]
            },
            {
              "event": "Headache",
              "values": [
                "2 (6.9%)"
              ]
            }
          ]
        },
        "serious_adverse_events": [
          "Atrial fibrillation: A total of 3 oHCM participants and 1 nHCM participant had new onset symptomatic atrial fibrillation",
          "Two of the atrial fibrillation events were considered SAEs",
          "None of the patients who had atrial fibrillation experienced LVEF <50% at any time"
        ],
        "discontinuation_details": "One oHCM participant discontinued treatment due to moderate dizziness. No other discontinuations reported.",
        "lvef_safety": {
          "narrative": "No meaningful reductions in LVEF or LVEF <50% were observed across a broad exposure range after EDG-7500 treatment. In the nHCM cohort, 4/12 (33%) participants had a baseline LVEF <60% by core lab; all 4 remained stable throughout the treatment period with a mean change from baseline of +2.5%. This is a key differentiation from cardiac myosin inhibitors (both approved and in development) which can cause systolic dysfunction and require careful LVEF monitoring through frequent echocardiographic evaluation. The lack of meaningful LVEF reduction potentially could eliminate the need for safety echocardiograms.",
          "findings": [
            "No LVEF <50% observed in any patient across entire study",
            "No meaningful reductions in LVEF observed in oHCM or nHCM cohorts",
            "4 nHCM participants with baseline LVEF <60% remained stable with +2.5% mean improvement",
            "Even patients with atrial fibrillation had no LVEF <50%",
            "No LVEF-related safety signals across broad exposure range"
          ]
        },
        "key_findings": [
          "Atrial fibrillation in 13.8% (4/29) with 2 SAEs is notable but none had LVEF compromise",
          "Dizziness in 27.6% was mostly mild and transient, leading to only 1 discontinuation",
          "No systolic dysfunction signals - major differentiation from myosin inhibitors",
          "Generally well tolerated across broad exposure range",
          "Special population: 4 nHCM patients with baseline LVEF <60% had stable/improved LVEF"
        ]
      }
    }
  },
  "catalysts": [
    {
      "event": "Longer-term CIRRUS-HCM data with intra-patient dose optimization results. Potential Phase 3 program initiation contingent on Phase 2 completion. Further characterization of atrial fibrillation signal and NT-proBNP correlation to pVO2 improvements.",
      "importance": "High"
    }
  ],
  "regulatory_path": {
    "status": "EDG-7500 is an investigational therapy not approved by any health authority. Phase 2 CIRRUS-HCM study ongoing with longer-term cohort exploring intra-patient dose optimization."
  },
  "investment_analysis": {
    "bull_case": [
      {
        "point": "EDG-7500 demonstrated robust efficacy across both obstructive and nonobstructive HCM with 89% (100mg dose) achieving complete LVOT-G response in oHCM and significant improvements in NT-proBNP, diastolic function (e'), KCCQ, and NYHA class in both populations. Critically, NO meaningful LVEF reductions or LVEF <50% were observed across a broad exposure range, potentially differentiating EDG-7500 from cardiac myosin inhibitors that require frequent safety echocardiograms due to systolic dysfunction risk. Atrial fibrillation occurred in 13.8% (4/29 patients, with 3 SAEs), which warrants monitoring but none had LVEF <50%.",
        "confidence": "Medium - single extraction"
      }
    ],
    "bear_case": [
      {
        "point": "Open-label design without placebo control - limits interpretation of subjective endpoints like KCCQ and NYHA",
        "probability": ""
      },
      {
        "point": "Small sample size (N=29 total; N=17 oHCM, N=12 nHCM) - limited statistical power",
        "probability": ""
      },
      {
        "point": "Short duration (4 weeks primary endpoint) - longer-term efficacy and safety unknown",
        "probability": ""
      },
      {
        "point": "Heterogeneous population: 5 oHCM participants had subthreshold LVOT-G on Day 1",
        "probability": ""
      },
      {
        "point": "Unequal dose group sizes at Week 4 (N=7 at 50mg, N=9 at 100mg in oHCM) limits dose comparison",
        "probability": ""
      },
      {
        "point": "Enriched population may limit generalizability - predominantly NYHA II/III, selected for symptoms",
        "probability": ""
      },
      {
        "point": "No assessment of exercise capacity (pVO2) in this dataset though mentioned as correlated endpoint",
        "probability": ""
      },
      {
        "point": "Preliminary data as of May 2025 - dataset may not be fully mature",
        "probability": ""
      },
      {
        "point": "Missing data: Not all patients had Week 4 assessments for all endpoints",
        "probability": ""
      },
      {
        "point": "No head-to-head comparison with approved HCM therapies (mavacamten, aficamten)",
        "probability": ""
      }
    ]
  }
}